Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ricardo Dent

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|January 27, 2017
Evidence-based goals in LDL-C reductionHandrean Soran, Ricardo Dent, Paul Durrington
International Journal of Clinical Practice|October 15, 2016
Very low LDL-C levels may safely provide additional clinical cardiovascular benefit: the evidence to dateTerry McCormack, Ricardo Dent, Mark Blagden
Advances in Therapy|July 19, 2017
Practical Considerations for the Use of Subcutaneous Treatment in the Management of DyslipidaemiaFranck Boccara, Ricardo Dent, Luis Ruilope, et al.
International Journal of Cardiology|October 12, 2016
Statin non-adherence and residual cardiovascular risk: There is need for substantial improvementMaciej Banach, Tomas Stulc, Ricardo Dent, et al.
Vascular Health and Risk Management|June 9, 2016
PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumabDirk J Blom, Ricardo Dent, Rita C Castro, et al.
European Journal of Preventive Cardiology|June 24, 2017
Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitorsIvan Pećin, Merel L Hartgers, G Kees Hovingh, et al.
International Journal of Clinical Practice|July 28, 2017
Anti-PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary careOlivier S Descamps, Uwe Fraass, Ricardo Dent, et al.
British Journal of Clinical Pharmacology|August 2, 2016
Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemiaIoanna Gouni-Berthold, Olivier S Descamps, Uwe Fraass, et al.
European Heart Journal|September 1, 2018
Why is hypercholesterolaemia so prevalent? A view from evolutionary medicineUlrich Laufs, Ricardo Dent, Paul J Kostenuik, et al.
Cardiovascular Drugs and Therapy|August 8, 2016
Erratum to: Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed HyperlipidemiaRobert S Rosenson, Terry A Jacobson, David Preiss, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|January 27, 2017
Evidence-based goals in LDL-C reductionHandrean Soran, Ricardo Dent, Paul Durrington
International Journal of Clinical Practice|October 15, 2016
Very low LDL-C levels may safely provide additional clinical cardiovascular benefit: the evidence to dateTerry McCormack, Ricardo Dent, Mark Blagden
Advances in Therapy|July 19, 2017
Practical Considerations for the Use of Subcutaneous Treatment in the Management of DyslipidaemiaFranck Boccara, Ricardo Dent, Luis Ruilope, et al.
International Journal of Cardiology|October 12, 2016
Statin non-adherence and residual cardiovascular risk: There is need for substantial improvementMaciej Banach, Tomas Stulc, Ricardo Dent, et al.
Vascular Health and Risk Management|June 9, 2016
PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumabDirk J Blom, Ricardo Dent, Rita C Castro, et al.
European Journal of Preventive Cardiology|June 24, 2017
Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitorsIvan Pećin, Merel L Hartgers, G Kees Hovingh, et al.
International Journal of Clinical Practice|July 28, 2017
Anti-PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary careOlivier S Descamps, Uwe Fraass, Ricardo Dent, et al.
British Journal of Clinical Pharmacology|August 2, 2016
Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemiaIoanna Gouni-Berthold, Olivier S Descamps, Uwe Fraass, et al.
European Heart Journal|September 1, 2018
Why is hypercholesterolaemia so prevalent? A view from evolutionary medicineUlrich Laufs, Ricardo Dent, Paul J Kostenuik, et al.
Cardiovascular Drugs and Therapy|August 8, 2016
Erratum to: Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed HyperlipidemiaRobert S Rosenson, Terry A Jacobson, David Preiss, et al.
Pageof 4